Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.40 |
| ▸ | FAP | Q12884 | 6/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.40 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260443 | 0.98 | DPP4 (0.41) | DPP4FAPDPP7XPNPEP1KMT2A | |
| SCHEMBL24260380 | 0.97 | DPP4 (0.43) | DPP4FAPDPP7XPNPEP1KMT2A | |
| SCHEMBL24260365 | 0.95 | XPNPEP1 (0.41) | DPP4FAPDPP7XPNPEP1KMT2A | |
| SCHEMBL24260372 | 0.90 | XPNPEP1 (0.38) | DPP4FAPDPP7XPNPEP1KMT2A | |
| SCHEMBL24260406 | 0.90 | F2 (0.40) | DPP4FAPDPP7XPNPEP1 | |
| SCHEMBL24260120 | 0.89 | XPNPEP1 (0.37) | DPP4FAPDPP7XPNPEP1 | |
| SCHEMBL24260304 | 0.89 | DPP4 (0.38) | DPP4FAPDPP7XPNPEP1DPP8 | |
| SCHEMBL24260148 | 0.87 | XPNPEP1 (0.38) | DPP4FAPDPP7XPNPEP1KMT2A | |
| SCHEMBL24260115 | 0.87 | XPNPEP1 (0.38) | DPP4FAPDPP7XPNPEP1KMT2A | |
| SCHEMBL24260247 | 0.83 | XPNPEP1 (0.42) | DPP4FAPDPP7XPNPEP1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPV2, TRPV3 | DPP4 99/4885FAP 56/4885DPP7 192/4885 |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | DPP4 746/4885FAP 108/4885DPP7 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.